GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
601
Atea Pharmaceuticals
AVIR
$267M
| $5.94K | ﹤0.01% |
+1,773
| New | +$5.94K |
|
|
ITOS
602
DELISTED
iTeos Therapeutics
ITOS
| $5.89K | ﹤0.01% |
+767
| New | +$5.89K |
|
603
Vanda Pharmaceuticals
VNDA
$272M
| $5.86K | ﹤0.01% |
+1,224
| New | +$5.86K |
|
604
AC Immune
ACIU
$229M
| $5.61K | ﹤0.01% |
+2,077
| New | +$5.61K |
|
605
Entergy
ETR
$39.2B
| $5.54K | ﹤0.01% |
+73
| New | +$5.54K |
|
606
Foghorn Therapeutics
FHTX
$326M
| $5.51K | ﹤0.01% |
+1,167
| New | +$5.51K |
|
607
Amylyx Pharmaceuticals
AMLX
$910M
| $5.44K | ﹤0.01% |
+1,439
| New | +$5.44K |
|
608
4D Molecular Therapeutics
FDMT
$340M
| $5.41K | ﹤0.01% |
+971
| New | +$5.41K |
|
609
C4 Therapeutics
CCCC
$194M
| $5.34K | ﹤0.01% |
+1,482
| New | +$5.34K |
|
610
Larimar Therapeutics
LRMR
$337M
| $5.19K | ﹤0.01% |
+1,340
| New | +$5.19K |
|
|
ARTV
611
Artiva Biotherapeutics, Inc. Common Stock
ARTV
$88.2M
| $5.14K | ﹤0.01% |
+510
| New | +$5.14K |
|
612
Inhibrx
INBX
$408M
| $4.68K | ﹤0.01% |
+304
| New | +$4.68K |
|
613
Lexeo Therapeutics
LXEO
$271M
| $4.57K | ﹤0.01% |
+694
| New | +$4.57K |
|
|
IGMS
614
DELISTED
IGM Biosciences
IGMS
| $4.38K | ﹤0.01% |
+716
| New | +$4.38K |
|
615
MacroGenics
MGNX
$126M
| $4.28K | ﹤0.01% |
+1,318
| New | +$4.28K |
|
616
Alector
ALEC
$305M
| $4.05K | ﹤0.01% |
+2,145
| New | +$4.05K |
|
|
CMPS
617
Compass Pathways
CMPS
$493M
| $4.04K | ﹤0.01% |
+1,068
| New | +$4.04K |
|
618
Fate Therapeutics
FATE
$116M
| $3.95K | ﹤0.01% |
+2,391
| New | +$3.95K |
|
619
Acrivon Therapeutics
ACRV
$41.8M
| $3.94K | ﹤0.01% |
+654
| New | +$3.94K |
|
620
Tevogen Bio Holdings
TVGN
$170M
| $3.79K | ﹤0.01% |
+3,676
| New | +$3.79K |
|
|
INZY
621
DELISTED
Inozyme Pharma
INZY
| $3.74K | ﹤0.01% |
+1,349
| New | +$3.74K |
|
622
scPharmaceuticals
SCPH
$299M
| $3.72K | ﹤0.01% |
+1,051
| New | +$3.72K |
|
623
Mersana Therapeutics
MRSN
$34M
| $3.71K | ﹤0.01% |
+104
| New | +$3.71K |
|
624
Nkarta
NKTX
$161M
| $3.69K | ﹤0.01% |
+1,482
| New | +$3.69K |
|
625
Kyverna Therapeutics
KYTX
$170M
| $3.39K | ﹤0.01% |
+906
| New | +$3.39K |
|